List of Excipients in Branded Drug GENTAMICIN

Generic Drugs Containing GENTAMICIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	gentamicin	0143-9128	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	gentamicin	0143-9128	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	gentamicin	0143-9128	PROPYLPARABEN
Hikma Pharmaceuticals USA Inc	gentamicin	0143-9128	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	gentamicin	0143-9128	SODIUM METABISULFITE
Hikma Pharmaceuticals USA Inc	gentamicin	0143-9128	SULFURIC ACID
Henry Schein Inc	gentamicin sulfate	0404-9866	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in GENTAMICIN?

# Of NDCs	Excipient
6	EDETATE DISODIUM
6	METHYLPARABEN
6	PROPYLPARABEN
10	SODIUM HYDROXIDE
6	SODIUM METABISULFITE
10	SULFURIC ACID
5	WATER

Gentamicin Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Gentamicin is a mature aminoglycoside antibiotic with low active-pharmaceutical-ingredient cost, extensive generic competition, and limited conventional patent protection. Commercial value is concentrated in formulation engineering rather than discovery of new chemical matter. The strongest opportunities are local-delivery systems, preservative-free multidose alternatives, ophthalmic and otic products, inhaled formulations, veterinary products, and combination products that reduce toxicity or improve adherence.

Excipient selection must address gentamicin’s high water solubility, polycationic structure, renal and ototoxicity risks, chemical compatibility, microbial control, and route-specific tolerability. The most defensible intellectual property is likely to arise from a defined delivery system, particle architecture, manufacturing process, or clinically supported pharmacokinetic profile rather than from basic aqueous gentamicin sulfate formulations.

What is gentamicin and which pharmaceutical forms are commercially important?

Gentamicin is an aminoglycoside antibiotic generally supplied as gentamicin sulfate, a mixture of related components produced by fermentation. It is used against susceptible aerobic Gram-negative organisms and selected Gram-positive infections in combination therapy. Systemic use is limited by nephrotoxicity, ototoxicity, and the need for therapeutic drug monitoring in many patients.

The principal dosage forms are:

Dosage form	Typical commercial role	Excipient priorities	Commercial attractiveness
Injectable solution	Hospital treatment of serious infections	Isotonicity, pH control, preservative strategy, low particulate burden	Low to moderate
Ophthalmic solution or ointment	Bacterial eye infections	Ocular tolerability, sterility, viscosity, preservative control	Moderate
Otic solution or suspension	External ear infections	Local retention, antimicrobial preservation, low irritation	Moderate
Topical cream or ointment	Skin infections	Spreadability, skin compatibility, microbial stability	Low to moderate
Inhaled or pulmonary formulation	Investigational or specialized local therapy	Aerosol performance, lung tolerability, particle engineering	High but technically difficult
Implant, hydrogel, or local depot	Surgical-site or bone-related delivery	Controlled release, tissue compatibility, sterilization	High
Veterinary formulations	Injectable, topical, ophthalmic, and otic use	Species-specific tolerability, cost, ease of administration	Moderate

FDA-approved gentamicin products include injectable formulations and topical, ophthalmic, and otic products marketed by multiple manufacturers. Product availability and labeling vary by manufacturer and jurisdiction. FDA product labeling identifies gentamicin sulfate as the active ingredient and provides route-specific formulation, dosing, contraindication, and warning requirements (U.S. Food and Drug Administration [FDA], n.d.-a; FDA, n.d.-b).

Which excipients are used in gentamicin formulations?

Gentamicin formulations commonly use simple excipient systems because the drug is readily soluble in water. The formulation challenge is less about solubilization than about maintaining chemical stability, sterility, dose uniformity, comfort, and compatibility with containers and delivery devices.

Injectable gentamicin excipients

Commercial injectable solutions may contain sodium chloride for isotonicity, sulfuric acid or sodium hydroxide for pH adjustment, and water for injection. Some multidose products use antimicrobial preservatives such as benzyl alcohol, depending on the label and patient population. Preservative selection is constrained in neonates, intrathecal use, and other sensitive populations.

Key development controls include:

• pH and osmolality
• visible and subvisible particulate matter
• extractables and leachables
• container closure integrity
• sterility and endotoxin control
• adsorption to tubing, bags, and administration sets
• compatibility with beta-lactam antibiotics and other co-administered drugs

A formulation using sodium chloride and pH adjustment has little differentiation value by itself. A stronger product concept would combine a preservative-free multidose delivery system, ready-to-administer packaging, or a stability advantage in a clinically relevant infusion container.

Ophthalmic and otic excipients

Ophthalmic solutions may use buffers, tonicity agents, viscosity modifiers, and preservatives. Benzalkonium chloride is a common ophthalmic preservative across the industry, but chronic exposure can irritate the ocular surface and damage epithelial cells. This creates an opportunity for preservative-free unit-dose packaging or alternative preservation systems.

Otic products can use viscosity enhancers or suspending agents to increase residence time in the ear canal. The formulation must account for the condition of the tympanic membrane. Aminoglycoside exposure in the middle or inner ear is a safety concern when the eardrum is perforated, and product labeling can restrict use in those circumstances.

Relevant excipient classes include:

Excipient class	Function	Gentamicin opportunity
Buffers	Maintain pH	Improve stability and local tolerability
Sodium chloride or other tonicity agents	Adjust osmolality	Reduce ocular or tissue irritation
Hydroxyethylcellulose, hypromellose, or similar polymers	Increase viscosity and residence time	Extend contact time in eye or ear
Carbomers or gel-forming polymers	Create in situ or topical gels	Enable sustained local exposure
Benzalkonium chloride and other preservatives	Control microbial contamination	Potential liability because of irritation
Chelating agents	Bind trace metals	May improve oxidative stability, subject to compatibility
Antioxidants	Limit degradation pathways	Require impurity and safety evaluation
Lipids and emulsifiers	Create ointments or emulsions	Support skin, ocular, or depot delivery
Biodegradable polymers	Control release	Enable implants, microspheres, and local depots

How should an excipient strategy address gentamicin stability?

Gentamicin is generally stable enough for conventional aqueous products, but formulation performance can be affected by pH, temperature, light, oxygen, trace metals, container interactions, and sterilization conditions. The precise degradation profile depends on the gentamicin sulfate composition and formulation matrix.

A practical stability strategy has four layers:

1. Control the aqueous environment. Use a narrowly justified pH range that balances chemical stability with tissue tolerability.
2. Limit trace-metal and oxidative pathways. Evaluate chelators and antioxidants through forced-degradation studies rather than assuming benefit.
3. Control sterilization stress. Compare terminal sterilization with aseptic processing and assess potency, impurities, color, osmolality, and container compatibility.
4. Validate the container system. Gentamicin may interact with elastomeric closures, plastic infusion components, filters, and adsorption-prone surfaces.

The most commercially useful stability claim would be tied to a specific presentation, such as room-temperature stability, extended in-use stability, or compatibility with a ready-to-administer infusion device. A broad claim that an excipient “improves stability” is unlikely to create durable market protection without comparative data and a defined product architecture.

What formulation patents could protect gentamicin products?

Basic gentamicin sulfate compositions are vulnerable to generic competition because the active ingredient and many conventional excipients are long established. New patent value is more likely in the following categories:

Controlled-release local delivery

Patents may cover gentamicin-loaded hydrogels, microspheres, beads, bone cements, coatings, films, wafers, or biodegradable implants. Claim strength depends on whether the product has:

• a defined polymer or carrier composition
• a specified release profile
• a clinically meaningful local concentration
• reduced systemic exposure
• improved surgical-site outcomes
• a reproducible manufacturing process

Local delivery is commercially attractive in orthopedic surgery, wound care, dental applications, and implant-associated infection management. The principal regulatory risk is that the product may be regulated as a drug, device, combination product, or drug-device combination depending on its delivery system and intended use.

Ophthalmic and otic delivery

Potential patent claims include in situ gels, mucoadhesive systems, preservative-free multidose devices, sustained-release inserts, and formulations that increase tissue residence while reducing dosing frequency.

A patent covering only a conventional viscosity modifier at routine concentration is generally weak. A stronger estate would link the formulation to a measurable pharmacokinetic or clinical result, such as longer precorneal residence, lower dosing frequency, or reduced preservative exposure.

Pulmonary delivery

Inhaled gentamicin could create a differentiated product by concentrating therapy in the respiratory tract while reducing systemic exposure. Potential technologies include dry powders, vibrating-mesh nebulizer solutions, liposomal carriers, and engineered microparticles.

Commercial barriers are substantial. Developers must demonstrate aerosol performance, lung deposition, local tolerability, immunogenicity, device compatibility, microbial control, and clinical benefit. For chronic pulmonary use, nephrotoxicity and ototoxicity remain relevant even when systemic exposure is reduced.

Combination products

Gentamicin may be combined with other antimicrobials, anti-inflammatory agents, wound-healing agents, or implant materials. Combination claims are strongest when the ingredients have a defined ratio, synergistic activity, controlled release, or a clear clinical use.

When does gentamicin lose exclusivity?

Gentamicin has no meaningful remaining innovator exclusivity in the conventional sense. It has been used clinically for decades, and generic gentamicin sulfate products are widely available. The original composition-of-matter and early formulation protections expired long ago. Current market access depends primarily on abbreviated regulatory pathways, product-specific manufacturing capability, supply reliability, and institutional purchasing.

Exclusivity category	Current commercial relevance
Original composition-of-matter patent	Expired
Conventional injectable formulation patents	Generally expired or commercially weak
FDA new-drug exclusivity	Not a meaningful barrier for mature generic products
Orphan-drug exclusivity	Product- and indication-specific, not inherent to gentamicin
Pediatric exclusivity	Depends on a specific FDA award and is not a general gentamicin right
New formulation patents	Potentially available
New method-of-use patents	Potentially available, subject to validity and enforceability
Device or manufacturing patents	Potentially available

FDA Orange Book-listed patents apply to specific approved products and sponsors, not automatically to every gentamicin product. Conventional generic injectable gentamicin generally has limited Orange Book-related litigation exposure compared with newer branded small molecules. A new gentamicin product could create a different patent profile if it is approved under a 505(b)(2) application or another pathway that relies partly on an existing reference product (FDA, n.d.-c).

What is the FDA regulatory status of gentamicin formulations?

FDA regulatory treatment depends on route, dosage form, intended use, and whether the product is an equivalent generic or a differentiated formulation.

Abbreviated new drug applications

A conventional injectable, ophthalmic, otic, or topical product may qualify for an abbreviated new drug application if it meets the relevant requirements for pharmaceutical equivalence, bioequivalence or therapeutic equivalence, quality, labeling, and manufacturing. The competitive advantage is speed and lower development cost, but the product remains exposed to generic pricing pressure.

505(b)(2) applications

A reformulated or locally delivered gentamicin product may use a 505(b)(2) pathway when it relies partly on FDA findings for an approved product but introduces a new dosage form, route, formulation, indication, or delivery technology. A 505(b)(2) product may obtain limited regulatory exclusivity and can support method-of-use or formulation patent listings where legally applicable.

Combination products

Gentamicin-loaded implants, bone cements, wound dressings, and drug-device systems may require coordinated FDA review. The lead center and evidentiary requirements depend on the product’s primary mode of action. Manufacturing controls must cover both drug quality and device or biomaterial performance.

How strong is the gentamicin patent estate?

The legacy gentamicin patent estate is weak for standard products and potentially strong for specialized delivery systems.

Patent category	Relative strength	Commercial assessment
Basic gentamicin sulfate solution	Low	Easy to design around; mature generic market
Preservative-free presentation	Low to moderate	Stronger when tied to a proprietary multidose device
Ophthalmic in situ gel	Moderate	Depends on polymer, concentration, residence time, and clinical benefit
Otic sustained-release formulation	Moderate	Attractive if dosing frequency and safety improve
Inhaled liposomal or dry-powder product	Moderate to high	Technical and clinical barriers support differentiation
Gentamicin implant or bone cement	Moderate to high	Claims can cover carrier, release, process, and use
Manufacturing process for high-purity gentamicin	Moderate	May support supply or quality differentiation
New therapeutic indication	Moderate	Patentability and enforceability depend on novelty and clinical evidence

Patent term adjustment, continuation practice, terminal disclaimers, prosecution history, and jurisdiction-specific validity must be assessed for each family. Broad claims directed to “gentamicin plus a polymer” face prior-art risk. Narrow claims with release specifications, particle size, device parameters, or clinical pharmacokinetic limitations may be more defensible but can be easier to design around.

Which companies are positioned in the gentamicin market?

The conventional market includes generic injectable and topical manufacturers, hospital suppliers, ophthalmic and otic product companies, and veterinary pharmaceutical companies. The relevant competitive groups include:

• generic sterile-injectable manufacturers
• contract development and manufacturing organizations
• ophthalmic and otic specialty companies
• orthopedic biomaterial companies
• wound-care and surgical-site infection companies
• veterinary pharmaceutical manufacturers
• inhalation-device and pulmonary drug-delivery developers

Competition is based less on brand recognition than on FDA compliance, sterile manufacturing capacity, shortage resilience, hospital contracts, packaging, and unit economics. A supplier with dependable gentamicin sulfate sourcing and low particulate or impurity performance may obtain a procurement advantage even without patent protection.

What commercial opportunities exist for gentamicin excipient innovation?

Preservative-free ophthalmic and otic products

Unit-dose packaging and preservative-free multidose devices can command a premium where ocular surface tolerability, chronic use, or postoperative care is important. The opportunity is strongest when the delivery system reduces contamination risk without imposing a material administration burden.

Long-acting local delivery

Gentamicin depots can reduce dosing frequency and provide high local exposure at surgical or infected sites. Orthopedic and dental applications are commercially relevant, but clinical positioning must distinguish prophylaxis from treatment and establish that local concentrations do not impair tissue healing or promote resistance.

Ready-to-administer injectable products

Premixed bags, prefilled syringes, and dose-banded hospital presentations can reduce preparation errors and pharmacy labor. The formulation opportunity lies in container compatibility, extended in-use stability, and preservative-free presentation rather than in a novel excipient alone.

Inhaled gentamicin

Pulmonary delivery has the highest potential value among nontraditional routes because it could improve the exposure-to-toxicity ratio. Development cost, clinical endpoint selection, device dependence, and chronic-use safety make this a high-risk program.

Veterinary products

Veterinary gentamicin has broader formulation flexibility, including otic, topical, injectable, and combination products. Species-specific dosing, withdrawal periods, antimicrobial stewardship, and residue requirements remain central to product development. The market can support differentiated packaging and administration systems even where human pharmaceutical pricing is compressed.

What generic entry risks exist for new gentamicin products?

A conventional gentamicin product faces immediate or near-immediate generic competition unless it has a meaningful formulation, device, indication, or regulatory barrier. A differentiated product faces different risks:

• a generic may copy the active ingredient and use a noninfringing excipient system
• a competitor may challenge formulation claims through Paragraph IV certification
• a 505(b)(2) product may face patent litigation under the Hatch-Waxman framework
• hospital buyers may substitute lower-cost conventional gentamicin
• clinical guidelines may favor alternative aminoglycosides or newer antibiotics
• local-delivery products may compete with vancomycin, tobramycin, or non-antibiotic biomaterials
• procurement decisions may prioritize supply assurance over formulation performance

Paragraph IV risk is most relevant when a new gentamicin product has Orange Book-listed patents. Standard generic gentamicin products are less likely to generate high-value Paragraph IV disputes because the underlying molecule and basic dosage forms are old.

How does gentamicin compare with tobramycin?

Gentamicin and tobramycin are both aminoglycosides, but their commercial positions differ.

Factor	Gentamicin	Tobramycin
Market maturity	Very mature	Mature, with strong pulmonary and ophthalmic relevance
Conventional injectable competition	High	High
Pulmonary opportunity	Selective	Stronger established role in cystic fibrosis
Ophthalmic opportunity	Established	Established
Toxicity profile	Nephrotoxicity and ototoxicity	Similar class concerns, with product-specific differences
Excipient differentiation	Local delivery, preservative-free products	Inhaled and specialty delivery systems
Patent opportunity	Mostly formulation and device based	Greater specialty-product precedent
Procurement pressure	High	High, but specialty indications can support premium pricing

Gentamicin’s lower-cost position can support hospital and veterinary products. Tobramycin has a stronger commercial precedent for chronic inhaled therapy, which raises the evidentiary bar for a new inhaled gentamicin product.

What revenue exposure does gentamicin create for manufacturers?

Revenue exposure is concentrated in volume rather than price. Standard injectable and topical products typically face low average selling prices and institutional purchasing pressure. A manufacturer’s financial risk comes from:

• sterile manufacturing interruptions
• active-ingredient supply concentration
• regulatory observations
• particulate or sterility failures
• hospital contract loss
• substitution by other aminoglycosides or broad-spectrum antibiotics
• low margins on commodity presentations

Higher-value revenue can come from products with a defined clinical or operational benefit: reduced dosing frequency, lower preservative exposure, lower administration cost, controlled local release, or improved adherence. Patent protection should be designed around these measurable benefits.

Key Takeaways

• Gentamicin’s conventional composition-of-matter and basic formulation protection has expired.
• Standard aqueous gentamicin sulfate products are commercially mature and exposed to generic price competition.
• Excipient innovation is most valuable when it creates a new delivery profile, not when it simply changes a buffer or tonicity agent.
• Preservative-free ophthalmic and otic products, ready-to-administer injectables, local depots, implants, and inhaled formulations offer the clearest commercial pathways.
• The strongest patent claims are likely to cover delivery systems, release profiles, manufacturing processes, devices, and clinically defined pharmacokinetic advantages.
• Paragraph IV litigation risk is limited for basic gentamicin products but can become material for patented 505(b)(2) formulations.
• Veterinary and surgical-site applications may offer better commercial differentiation than commodity hospital injectables.
• Product value depends on sterile manufacturing reliability, container compatibility, clinical positioning, and procurement economics as much as on excipient selection.

FAQs

Can gentamicin be formulated as a preservative-free multidose product?

Yes. A preservative-free multidose product generally requires a validated container-closure and dispensing system that limits microbial ingress. The device, in-use stability, sterility assurance, and labeling would be central to regulatory and patent value.

Are gentamicin-loaded bone cements patentable?

Potentially. Patentability may arise from the cement composition, gentamicin loading, particle distribution, release profile, curing behavior, manufacturing method, or defined surgical use. Older gentamicin bone-cement disclosures create substantial prior-art constraints.

Which excipients can increase gentamicin tissue residence?

Viscosity modifiers, mucoadhesive polymers, gels, liposomes, microspheres, and biodegradable matrices can increase local residence. The relevant commercial question is whether residence time improves clinical outcomes without delaying clearance or increasing toxicity.

Is gentamicin suitable for liposomal drug delivery?

It can be incorporated into specialized liposomal or nanoparticle systems, but its hydrophilic and cationic properties make loading efficiency, leakage control, sterilization, scale-up, and release control important development issues.

Can a gentamicin formulation receive new market exclusivity?

A differentiated product may qualify for limited regulatory exclusivity depending on its approval pathway, indication, and statutory requirements. Formulation and method-of-use patents may provide separate protection, but exclusivity is product-specific and does not extend automatically to all gentamicin products.

References

1. U.S. Food and Drug Administration. (n.d.-a). Gentamicin sulfate injection prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.-b). Gentamicin ophthalmic, otic, and topical product labeling. FDA labeling database.

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.-d). ANDA submissions: Content and format. FDA Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.-e). 505(b)(2) applications. FDA Center for Drug Evaluation and Research.

6. Mingeot-Leclercq, M.-P., & Tulkens, P. M. (1999). Aminoglycosides: Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 43(5), 1003-1012.

7. Forge, A., & Schacht, J. (2000). Aminoglycoside antibiotics. Audiology and Neurotology, 5(1), 3-22.

8. World Health Organization. (2019). WHO report on surveillance of antibiotic consumption: 2016-2018. World Health Organization.